Status: Recruiting
EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
The EPOCH study population is patients with tubo-ovarian carcinosarcoma or uterine carcinosarcoma with evidence of recurrence or progression. The study aims to determine the activity of eribulin as a single agent and the combination of eribulin and pembrolizumab as measured by clinical benefit rate (CBR) at 12 weeks. Additionally, the study aims to establish whether high mobility group A2 (HMGA2) protein expression is a good functional biomarker to predict response to eribulin and pembrolizumab.
Participants needed: 30
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Australia New Zealand Gynaecological Oncology GroupUpdated: Feb 4, 2025Locations: 6
Eligibility criteria
Provision of written informed consent prior to any study specific procedures and... [+17]
Prior line of treatment involving immunotherapy with an anti-PD-1, anti-PD-L1, o... [+19]